Armstrong AW, Hee Park S, Chirikov V, Nicolas P, Wang W-J, Colombo MJ, Patel V. Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial. J of Skin [Internet]. 2022Nov.16 [cited 2024Apr.19];6(6):s62. Available from: https://jofskin.org/index.php/skin/article/view/1817